Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model

Transfusion

Volumn 55, Issue 3, 2015, Pages 532-543

  Okoye, Obi T ^a   Reddy, Heather ^b   Wong, Monica D ^a   Doane, Suzann ^b   Resnick, Shelby ^a   Karamanos, Efstathios ^a   Skiada, Dimitra ^a   Goodrich, Raymond ^b   Inaba, Kenji ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CaridianBCT Biotechnologies LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; METHEMOGLOBIN; RIBOFLAVIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; BLOOD CLOTTING; BLOOD TRANSFUSION; BLOOD VOLUME; CONTROLLED STUDY; COOLING; ERYTHROCYTE; FEMALE; HEMODILUTION; HISTOPATHOLOGY; IN VIVO STUDY; LEUKOCYTE; LIVER INJURY; MALE; MEAN ARTERIAL PRESSURE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; OPERATIVE BLOOD LOSS; PARTIAL THROMBOPLASTIN TIME; PATHOGEN REDUCTION SYSTEM; PORCINE MODEL; POSTOPERATIVE CARE; PROTHROMBIN TIME; RESUSCITATION; THROMBOCYTE; THROMBOELASTOGRAPHY; TISSUE OXYGENATION; ULTRAVIOLET RADIATION; ANIMAL; BLOOD; BLOOD CELL; BLOOD CLOTTING TEST; BLOOD SAFETY; BLOOD STORAGE; COMPARATIVE STUDY; COMPLICATION; DRUG EFFECTS; EVALUATION STUDY; HEMORRHAGE; INDUCED HYPOTHERMIA; INJURIES; LACERATIONS; LAPAROTOMY; LIVER; MEAN CORPUSCULAR VOLUME; PATHOLOGY; PIG; PROCEDURES; RADIATION RESPONSE; RANDOMIZATION;

ANIMALS; BLOOD; BLOOD CELLS; BLOOD COAGULATION TESTS; BLOOD PRESERVATION; BLOOD SAFETY; BLOOD TRANSFUSION; ERYTHROCYTE INDICES; FEMALE; HEMODILUTION; HEMORRHAGE; HYPOTHERMIA, INDUCED; LACERATIONS; LAPAROTOMY; LIVER; MALE; RANDOM ALLOCATION; RESUSCITATION; RIBOFLAVIN; SUS SCROFA; SWINE; THROMBELASTOGRAPHY; ULTRAVIOLET RAYS;

EID: 84924603324     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12894     Document Type: Article

References (51)

1. Borgman MA, Spinella PC, Perkins JG, et-al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63: 805-813.
2. Holcomb JB, Wade CE, Michalek JE, et-al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248: 447-458.
3. Inaba K, Lustenberger T, Rhee P, et-al. The impact of platelet transfusion in massively transfused trauma patients. J Am Coll Surg 2010; 211: 573-579.
4. Rowell SE, Barbosa RR, Diggs BS, et-al. Effect of high product ratio massive transfusion on mortality in blunt and penetrating trauma patients. J Trauma 2011; 71 (Suppl 3): S353-357.
5. Sperry JL, Ochoa JB, Gunn SR, et-al. An FFP:PRBC transfusion ratio >/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65: 986-993.
6. Wafaisade A, Maegele M, Lefering R, et-al. High plasma to red blood cell ratios are associated with lower mortality rates in patients receiving multiple transfusion (4
7. Spinella PC, Perkins JG, Grathwohl KW, et-al. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma 2009; 66 (Suppl): S69-76.
8. Hakre S, Manak MM, Murray CK, et-al. Transfusion-transmitted human T-lymphotropic virus type I infection in a United States military emergency whole blood transfusion recipient in Afghanistan, 2010. Transfusion 2013; 53: 2176-2182.
9. Spinella PC, Perkins JG, Grathwohl KW, et-al. Risks associated with fresh whole blood and red blood cell transfusions in a combat support hospital. Crit Care Med 2007; 35: 2576-2581.
10. Kauvar DS, Holcomb JB, Norris GC, et-al. Fresh whole blood transfusion: a controversial military practice. J Trauma 2006; 61: 181-184.
11. Seghatchian J, Struff WG, Reichenberg S,. Main properties of the THERAFLEX MB-plasma system for pathogen reduction. Transfus Med Hemother 2011; 38: 55-64.
12. Seltsam A, Muller TH,. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 2013; 162: 442-454.
13. Henschler R, Seifried E, Mufti N,. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38: 33-42.
14. Fast LD, Nevola M, Tavares J, et-al. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease? Transfusion 2013; 53: 373-381.
15. Goodrich RP, Doane S, Reddy HL,. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products. Biologicals 2010; 38: 20-30.
16. Reddy HL, Doane SK, Keil SD, et-al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013; 53 (Suppl 1): 131S-136.
17. Keil SD, Rapaport R, Doane SK, et-al. Viral reduction of intracellular HIV using the Mirasol system for whole blood. Vox Sang 2012; 103 (Suppl. S1): 144.
18. Tonnetti L, Thorp AM, Reddy HL, et-al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013; 53: 860-867.
19. Tonnetti L, Thorp AM, Reddy HL, et-al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012; 52: 409-416.
20. Tonnetti L, Thorp AM, Reddy HL, et-al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2014. doi: 10.1111/trf.12820.
21. Olver CS, Martinez CR, Keil SD, et-al. Treatment of P.-falciparum contaminated whole blood units using the Mirasol system for whole blood. Vox Sang 2014; 107 (Suppl. S1): 131.
22. Schnuriger B, Inaba K, Barmparas G, et-al. A new survivable damage control model including hypothermia, hemodilution, and liver injury. J Surg Res 2011; 169: 99-105.
23. Cotton BA, Podbielski J, Camp E, et-al. A randomized controlled pilot trial of modified whole blood versus component therapy in severely injured patients requiring large volume transfusions. Ann Surg 2013; 258: 527-532; discussion 532-3.
24. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med 2001; 11: 149-175.
25. Parsyan A, Candotti D,. Human erythrovirus B19 and blood transfusion-an update. Transfus Med 2007; 17: 263-278.
26. Klein HG,. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2005; 257: 224-237.
27. McCullough J,. Progress toward a pathogen-free blood supply. Clin Infect Dis 2003; 37: 88-95.
28. Grellier P, Benach J, Labaied M, et-al. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008; 48: 1676-1684.
29. Goodrich RP,. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78 (Suppl 2): 211-215.
30. Corash L,. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apher Sci 2001; 25: 179-181.
31. Purmal A, Valeri CR, Dzik W, et-al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002; 42: 139-145.
32. Cadet J, Decarroz C, Wang SY, et-al. Mechanisms and products of photosensitized degradation of nucleic acids and related model compounds. Isr J Chem 1983; 23: 420-429.
33. Tonnetti L, Proctor MC, Reddy HL, et-al. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion 2010; 50: 1019-1027.
34. Vanlandingham DL, Keil SD, Horne KM, et-al. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system. Transfusion 2013; 53: 284-290.
35. Keil SD, Kiser P, Sullivan JJ, et-al. Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfusion 2013; 53: 2278-2286.
36. Jocic M, Trkuljic M, Jovicic D, et-al. Mirasol PRT system inactivation efficacy evaluated in platelet concentrates by bacteria-contamination model. Vojnosanit Pregl 2011; 68: 1041-1046.
37. Fast LD, Dileone G, Li J, et-al. Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46: 642-648.
38. Mintz PD, Wehrli G,. Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products. Bone Marrow Transplant 2009; 44: 205-211.
39. Fast LD,. Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158: 563-568.
40. Cancelas JA, Rugg N, Fletcher D, et-al. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011; 51: 1460-1468.
41. Kahn C,. The Merck veterinary manual. 10th ed. Whitehouse Station (NJ): Merck & Co; 2010.
42. Plumb DC,. Plumb's veterinary drug handbook. 7th ed. Stockholm (WI): PharmaVet Inc.; 2011.
43. Hannon JP, Bossone CA, Wade CE,. Normal physiological values for conscious pigs used in biomedical research. Lab Anim Sci 1990; 40: 293-298.
44. Hughes JD, Macdonald VW, Hess JR,. Warm storage of whole blood for 72 hours. Transfusion 2007; 47: 2050-2056.
45. Sartorelli P, Paltrinieri S, Agnes F, et-al. Role of inosine in prevention of methaemoglobinaemia in the pig: in vitro studies. Zentralbl Veterinarmed A 1996; 43: 489-493.
46. Bartelmaos T, Chabanel A, Leger J, et-al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2013; 53: 1335-1345.
47. Zimmermann R, Wintzheimer S, Weisbach V, et-al. Influence of prestorage leukoreduction and subsequent irradiation on in vitro red blood cell (RBC) storage variables of RBCs in additive solution saline-adenine-glucose-mannitol. Transfusion 2009; 49: 75-80.
48. Alam HB, Hamwi KB, Duggan M, et-al. Hemostatic and pharmacologic resuscitation: results of a long-term survival study in a swine polytrauma model. J Trauma 2011; 70: 636-645.
49. Ryan ML, Thorson CM, King DR, et-al. Insertion of central venous catheters induces a hypercoagulable state. J Trauma Acute Care Surg 2012; 73: 385-390.
50. Neate SL, Boysen SR, Wagg CR, et-al. Comparison of thromboelastography parameters between different catheter lumen diameters in an uncontrolled haemorrhagic shock model in swine. Blood Coagul Fibrinolysis 2013; 24: 581-586.
51. Sondeen JL, de Guzman R, Amy Polykratis I, et-al. Comparison between human and porcine thromboelastograph parameters in response to ex-vivo changes to platelets, plasma, and red blood cells. Blood Coagul Fibrinolysis 2013; 24: 818-829.